We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That was before this announcement about a massive drive for antibiotic drug development.
Come on catch up. You’re starting to sound a little slow
That was then lad, this is now.
But when Motif Inc delisted and got wound down they put iclaprim up for sale and no one wanted it
Lol, Bobby always has something negative to say. You have to admit though lad, iclaprim might be useful to someone.
But a massive pharmaceutical corp may look at a buyout of MTFB and all the r&d that they have done for say £10m?
Now that’s a cheap and fast way to get a Development drug that with another £20m in research could lead to a product on the market in 18-24 months
“We are not looking to fund big companies; we are looking for those that lack appropriate funding to forward their research to all the way to registration and access to market,” said Hubertus von Baumbach, CEO of Boehringer Ingelheim, one of the pharma companies backing the fund.
This extract is on the sciencebusiness.net website
If you take a look at the part where they will help companies to register and access market I think this is where MTFB come in...?
We'll see ;-)
Those articles may be fine for Bio companies that have a lab or labs that are currently doing drug trials or coming up with new drug idea's with top scientists.....
But Motif are just a cash shell, so can't see it effecting Motif as these big pharma companies wont be looking for a listing on AIM...
https://sciencebusiness.net/news/pharma-industry-launches-1-billion-initiative-find-new-antibiotics
The current market failure has led the antibiotic pipeline to “the verge of collapse,” said David Ricks, CEO of US pharma Eli Lilly, who is president of the pharmaceutical industry body IFPMA. “The AMR Action Fund will support innovative antibiotic candidates through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline,” Dicks said.
BOOM!! https://www.nytimes.com/2020/07/09/health/antibiotics-pharma-drug-resistance.html